Sonoma Pharmaceuticals 

€0
22
+€0+0% 今天

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

財報

10Feb預期
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-1.15
-0.8
-0.46
-0.11
預期EPS
-0.24391029999999997
實際EPS
-0.2956949799

財務

-24.24%利潤率
未盈利
2019
2020
2021
2022
2023
2024
26.5M營收
-6.42M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 O8Z.F 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Show more...
執行長
Ms. Amy M. Trombly Esq., J.D.
員工
10
國家
US
ISIN
US83558L3033
WKN
000A40M9J

上市

0 Comments

分享你的想法

FAQ

Sonoma Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Sonoma Pharmaceuticals 的股票以代號 O8Z.F 進行交易。
Sonoma Pharmaceuticals 下一次財報日期是什麼時候?
Sonoma Pharmaceuticals 將於 July 15, 2026 公布下一次財報。
Sonoma Pharmaceuticals 上一季度的財報如何?
O8Z.F 上一季度的財報為每股 -0.3 EUR,預估為 -0.24 EUR,帶來 -21.23% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Sonoma Pharmaceuticals 去年的營收是多少?
Sonoma Pharmaceuticals 去年的營收為 26.5MEUR。
Sonoma Pharmaceuticals 去年的淨利是多少?
O8Z.F 去年的淨收益為 -6.42MEUR。
Sonoma Pharmaceuticals 有多少名員工?
截至 April 03, 2026,公司共有 10 名員工。
Sonoma Pharmaceuticals 位於哪個產業?
Sonoma Pharmaceuticals從事於Health Care產業。
Sonoma Pharmaceuticals 何時完成拆股?
Sonoma Pharmaceuticals 上次拆股發生於 August 30, 2024,比例為 1:20。
Sonoma Pharmaceuticals 的總部在哪裡?
Sonoma Pharmaceuticals 的總部位於 US 的 Boulder。